ArticleSeizure2026
New onset seizure etiologies and outcomes among adults with HIV in the era of broadly available antiretroviral therapies.
Article in Seizure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesIn this era of widely available antiretroviral therapy (ART), information regarding new onset seizure, seizure recurrence and mortality is needed to guide clinical decision-making.
methodsA rural, prospective, cohort study was conducted April 2016 to June 2019. Inclusion criteria were HIV positivity, age ≥ 18 years, and new onset seizure. Two-year seizure recurrence was the outcome. Risk factors for seizure recurrence were evaluated using a Fine-Gray model to account for the competing outcome of death.
results258 people were screened, 95 were eligible and 89 were enrolled. 47 (53 %) were female, mean 39 years, and 64 (72 %) were on antiretroviral therapy (ART). Only 25/64 (39 %) of these were virally suppressed. At presentation, 12 (13 %) were in status epilepticus and 46 (52 %) had multiple or prolonged seizures. The commonest seizure etiology was cryptococcal meningitis, 18 (20%). At discharge, 6 (7 %) patients were prescribed antiseizure medications (ASM). Follow-up was exclusively directed to ART Clinics. After median 585 days, 24 % (21/89) developed epilepsy with multiple seizure recurrences. No one was consistently maintained on ASM. A history of prior central nervous system (CNS) injury was associated with seizure recurrence (HR 5.1;95 %CI1.9-13.2;p = 0.0001). Epilepsy development was less likely in individuals with a worse HIV disease stage (HR 0.2; 95 %CI 0.1-0.5;p = 0.002). Mortality was 37 % (n = 33). SIGNIFICANCE: Despite high and early mortality, among rural persons living with HIV who have new onset seizure, almost a quarter will go on to develop epilepsy. Prior CNS injury was a risk factor for epilepsy. Having more advanced HIV disease was protective against epilepsy suggesting that if conditions associated with advanced HIV disease are the underlying cause of new onset seizures, once HIV is treated, seizure recurrence risk is reduced. Better models of care are needed that include dedicated epilepsy care which was neglected in the HIV clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.